Catalent (CTLT) SVP Sells $94,088.56 in Stock

Catalent (NYSE:CTLT) SVP Steven L. Fasman sold 2,252 shares of the company’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total transaction of $94,088.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Catalent stock traded down $0.37 during trading hours on Thursday, reaching $42.15. The stock had a trading volume of 29,034 shares, compared to its average volume of 725,742. The company has a market cap of $5.58 billion, a P/E ratio of 31.50, a price-to-earnings-growth ratio of 2.03 and a beta of 1.50. Catalent has a twelve month low of $33.42 and a twelve month high of $47.87. The company has a debt-to-equity ratio of 2.53, a quick ratio of 1.78 and a current ratio of 2.18.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, May 1st. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.06. The business had revenue of $627.90 million during the quarter, compared to the consensus estimate of $610.47 million. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The company’s revenue was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 earnings per share. equities research analysts forecast that Catalent will post 1.55 EPS for the current year.

Several institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. raised its position in shares of Catalent by 5.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 29,439 shares of the company’s stock worth $1,209,000 after acquiring an additional 1,430 shares during the period. Mason Street Advisors LLC raised its position in shares of Catalent by 2.3% during the 1st quarter. Mason Street Advisors LLC now owns 66,961 shares of the company’s stock worth $2,749,000 after purchasing an additional 1,505 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of Catalent by 4.3% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 41,420 shares of the company’s stock worth $1,701,000 after purchasing an additional 1,690 shares during the last quarter. Allianz Asset Management GmbH raised its position in shares of Catalent by 0.3% during the 1st quarter. Allianz Asset Management GmbH now owns 710,919 shares of the company’s stock worth $29,190,000 after purchasing an additional 2,021 shares during the last quarter. Finally, Amalgamated Bank raised its position in shares of Catalent by 12.8% during the 4th quarter. Amalgamated Bank now owns 19,502 shares of the company’s stock worth $801,000 after purchasing an additional 2,212 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, March 9th. Raymond James raised shares of Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a report on Wednesday, March 21st. They noted that the move was a valuation call. UBS Group raised shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 21st. KeyCorp raised shares of Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price target on the stock in a report on Wednesday, March 28th. Finally, ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, June 5th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $45.67.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply